Humacyte announces presentations at VEITHsymposium on ATEV results

Humacyte (HUMA) announced highlights of five podium presentations on the Company’s acellular tissue engineered vessel, ATEV, made yesterday at the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons, in New York, NY. The ATEV’s ability to remodel into living vascular tissue was highlighted in a podium presentation titled “In Vivo Regeneration of Bioengineered Blood Vessels: Histologic Evaluation of Acellular Tissue Engineered Vessels After Long-Term Clinical Use,” by Luigi Pascarella, MD, Division Chief of Vascular Surgery, Associate Chair of Education, UNC Medical School. The presentation described a study in which tissue samples from ATEVs implanted in patients, taken up to 200 weeks post implantation, were analyzed using immunochemistry. The ATEVs are decellularized at the end of the production process to eliminate immunogenicity and allow them to be universally implanted into any patient without fear of rejection. Post-implantation analysis of the ATEVs revealed progressive recellularization with host cells including smooth muscle cells and endothelial cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels.